Simply Wall St.
Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?
➖
AI Sentiment
Neutral
4/10
- Home
- VYGR
as of 03-17-2026 2:22pm EST
$3.96
$0.36
-8.33%
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 194.0M | IPO Year: | 2015 |
| Target Price: | $17.00 | AVG Volume (30 days): | 783.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -2.04 | EPS Growth: | -80.53 |
| 52 Week Low/High: | $2.65 - $5.55 | Next Earning Date: | 06-10-2026 |
| Revenue: | $10,135,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 54.19% | Revenue Growth (next year): | 20.22% |
| P/E Ratio: | -1.94 | Index: | N/A |
| Free Cash Flow: | -135063000.0 | FCF Growth: | N/A |
AI-Powered VYGR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 19 hours ago
AI Recommendation
hold
Model Accuracy: 71.43%
71.43%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Voyager Therapeutics Inc. (VYGR)
Jorgensen Nathan D.
Sell
Chief Financial Officer
VYGR Feb 24, 2026
Avg Cost/Share
$3.77
Shares
4,668
Total Value
$17,598.36
Owned After
151,416
SEC Form 4
Sandrock Alfred
Sell
President and CEO
VYGR Feb 24, 2026
Avg Cost/Share
$3.79
Shares
14,197
Total Value
$53,806.63
Owned After
484,060
SEC Form 4
Swartz Robin
Sell
COO & CBO
VYGR Feb 24, 2026
Avg Cost/Share
$3.77
Shares
6,458
Total Value
$24,346.66
Owned After
199,738
SEC Form 4
Carter Todd Alfred
Sell
Chief Scientific Officer
VYGR Feb 24, 2026
Avg Cost/Share
$3.76
Shares
4,174
Total Value
$15,694.24
Owned After
145,718
SEC Form 4
Sandrock Alfred
Sell
President and CEO
VYGR Feb 18, 2026
Avg Cost/Share
$3.41
Shares
11,732
Total Value
$40,006.12
Owned After
484,060
SEC Form 4
Swartz Robin
Sell
COO & CBO
VYGR Feb 18, 2026
Avg Cost/Share
$3.44
Shares
3,882
Total Value
$13,354.08
Owned After
199,738
SEC Form 4
Carter Todd Alfred
Sell
Chief Scientific Officer
VYGR Feb 18, 2026
Avg Cost/Share
$3.44
Shares
3,301
Total Value
$11,355.44
Owned After
145,718
SEC Form 4
Sandrock Alfred
Sell
President and CEO
VYGR Feb 10, 2026
Avg Cost/Share
$3.78
Shares
12,192
Total Value
$46,085.76
Owned After
484,060
SEC Form 4
Swartz Robin
Sell
COO & CBO
VYGR Feb 10, 2026
Avg Cost/Share
$3.85
Shares
4,569
Total Value
$17,590.65
Owned After
199,738
SEC Form 4
Carter Todd Alfred
Sell
Chief Scientific Officer
VYGR Feb 10, 2026
Avg Cost/Share
$3.85
Shares
3,525
Total Value
$13,571.25
Owned After
145,718
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Jorgensen Nathan D. | VYGR | Chief Financial Officer | Feb 24, 2026 | Sell | $3.77 | 4,668 | $17,598.36 | 151,416 | |
| Sandrock Alfred | VYGR | President and CEO | Feb 24, 2026 | Sell | $3.79 | 14,197 | $53,806.63 | 484,060 | |
| Swartz Robin | VYGR | COO & CBO | Feb 24, 2026 | Sell | $3.77 | 6,458 | $24,346.66 | 199,738 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Feb 24, 2026 | Sell | $3.76 | 4,174 | $15,694.24 | 145,718 | |
| Sandrock Alfred | VYGR | President and CEO | Feb 18, 2026 | Sell | $3.41 | 11,732 | $40,006.12 | 484,060 | |
| Swartz Robin | VYGR | COO & CBO | Feb 18, 2026 | Sell | $3.44 | 3,882 | $13,354.08 | 199,738 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Feb 18, 2026 | Sell | $3.44 | 3,301 | $11,355.44 | 145,718 | |
| Sandrock Alfred | VYGR | President and CEO | Feb 10, 2026 | Sell | $3.78 | 12,192 | $46,085.76 | 484,060 | |
| Swartz Robin | VYGR | COO & CBO | Feb 10, 2026 | Sell | $3.85 | 4,569 | $17,590.65 | 199,738 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Feb 10, 2026 | Sell | $3.85 | 3,525 | $13,571.25 | 145,718 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Mar 9, 2026 · 95% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYMar 9, 2026 · 95% conf.
AI Prediction BUY
1D
+3.38%
$4.25
Act: +27.32%
5D
+12.81%
$4.64
20D
+12.54%
$4.63
Price: $4.11 Prob +5D: 98% AUC: 1.000
0001104659-26-025201
Voyager Therapeutics, Inc._March 9, 2026 0001640266false00016402662026-03-092026-03-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 9, 2026
Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37625 46-3003182
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
75 Hayden Avenue Lexington, Massachusetts 02421
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (857) 259-5340 Not Applicable (Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value
VYGR
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On March 9, 2026, Voyager Therapeutics, Inc. (the “Company”) announced fourth quarter and full year 2025 financial results and corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
Exhibit No. Description
99.1 Press release dated March 9, 2026 entitled “Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results”.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ar
Date: March 9, 2026
VOYAGER THERAPEUTICS, INC.
By: /s/ Alfred Sandrock, M.D., Ph.D.
Alfred Sandrock, M.D., Ph.D.
Chief Executive Officer, President, and Director (Principal Executive Officer)
3
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 10, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 10, 2025 · 100% conf.
AI Prediction SELL
1D
-4.11%
$4.08
Act: +0.00%
5D
-9.35%
$3.86
Act: -3.52%
20D
-11.90%
$3.75
Act: +0.70%
Price: $4.26 Prob +5D: 0% AUC: 1.000
0001104659-25-108841
Voyager Therapeutics, Inc._November 10, 2025 0001640266false00016402662025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 10, 2025
Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37625 46-3003182
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
75 Hayden Avenue Lexington, Massachusetts 02421
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (857) 259-5340
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value
VYGR
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On November 10, 2025, Voyager Therapeutics, Inc. (the “Company”) announced third quarter 2025 financial results and corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
Exhibit No. Description
99.1 Press release dated November 10, 2025 entitled “Voyager Reports Third Quarter 2025 Financial and Operating Results”.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ar
Date: November 10, 2025
VOYAGER THERAPEUTICS, INC.
By: /s/ Alfred Sandrock, M.D., Ph.D.
Alfred Sandrock, M.D., Ph.D.
Chief Executive Officer, President, and Director (Principal Executive Officer)
3
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 6, 2025
0001558370-25-010507
0001640266false00016402662025-08-062025-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2025
Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware 001-37625 46-3003182
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
75 Hayden Avenue Lexington, Massachusetts 02421
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (857) 259-5340
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value
VYGR
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On August 6 2025, Voyager Therapeutics, Inc. (the “Company”) announced second quarter 2025 financial results and corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits (d) Exhibits The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
Exhibit No. Description
99.1 Press release dated August 6, 2025 entitled “Voyager Reports Second Quarter 2025 Financial and Operating Results”.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ar
Date: August 6, 2025
VOYAGER THERAPEUTICS, INC.
By: /s/ Alfred Sandrock, M.D., Ph.D.
Alfred Sandrock, M.D., Ph.D.
Chief Executive Officer, President, and Director (Principal Executive Officer)
3
Latest Voyager Therapeutics Inc. News
VYGR Breaking Stock News: Dive into VYGR Ticker-Specific Updates for Smart Investing
Compare VYGR vs Leading Stocks
See how VYGR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VYGR Voyager Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.